Drug Trial Radar · NCT01828463
Dose Response Study of Nitisinone in Alkaptonuria
Last checked: Nov 19, 2026Latest source record: Jun 11, 2014 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
40
Actual
Start
May 2013
Primary completion
Oct 2013
Study completion Dec 2013
Sponsor
- Lead sponsor
- University of LiverpoolAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Liverpool University Hospitals NHS Foundation Trust
- First posted
- Apr 10, 2013
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
SONIA 1 is an international, multicentre, randomised, open-label, no-treatment controlled, parallel group, dose-response study to investigate the effect of once daily nitisinone on 24-hour urinary homogentisic acid excretion in patients with alkaptonuria after 4-weeks treatment. They study will identify the optimal dose to decrease urine homogentisic acid to near normal levels.
Conditions
- Alkaptonuria
Interventions
NitisinoneDrug
doses 1, 2, 4 \& 8 mg plus no treatment arm
Primary outcomes
What the sponsor says the trial is designed to measure.
- dose of nitisinone that decreases urinary homogentisic acid to near normalTime frame: 4 weeks
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Royal Liverpool Hospital
Liverpool, Merseyside, United Kingdom
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.